Clinical Trial Update: Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC [Phase 1]

View source ↗

Summary

An open-label Phase 1b dose-escalation trial of a micellar docetaxel formulation in metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Docetaxel (micellar formulation) (docetaxel)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: TERMINATED